Overview

* Company advancing rese-cel clinical trials with promising data for autoimmune diseases

* Cabaletta expects cash reserves to fund operations into the second half of 2026

Outlook

* Cabaletta plans BLA submission for rese-cel in 2027

* Company expects FDA alignment on cohort designs by end of 2025

* Cabaletta anticipates enrollment in registrational cohorts in 2026

Result Drivers

* Research and development expenses were $39.8 million for the three months ended September 30, 2025, compared to $26.3 million for the same period in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net Beat -$44.87 -$45.55

Income mln mln (6

Analysts

)

Q3 -$46.59

Income mln

from

Operatio

ns

Q3 $46.59

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Cabaletta Bio Inc ( CABA ) is $14.50, about 82.4% above its November 7 closing price of $2.55

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)